Abstract: The present invention relates to potent antibacterial activity of novel bisbenzimidazoles (SP12a and SP12b) against both Gram positive and Gram negative bacteria and a synergistic composition comprising Bisbenzimidazole (HN12b) in combination with Efflux pump inhibitors against most of the pathogenic bacterial strains.

Abstract: The invention relates to a material, process and method for the selective analysis of small molecules. Particularly the invention provides a material and a technique for the analysis of small molecules excluding other large molecular weight (MW) analytes. The process involves selective detection of low molecular weight molecules from a sample comprising the steps of placing said sample with SBA-15 particles; and subjecting the same to desorption ionization mass spectrometry, wherein low molecular weight molecules are selectively detected over the higher molecular weight molecules. A kit for the selective analysis of small molecules is also provided.

Abstract: The present invention relates to dual activation of Akt/NF?B pathway by DMA (5-(4-methylpiperazin-1-yl)-2-[2?-(3,4-dimethoxyphenyl)-5?-benzimidazolyl]benzimidazole) to render radioprotection both in mammalian cells and in Balb/c mice. Further it selectively protects normal cells overs tumor tissues against lethal total body irradiation (TBI) and there was no activation of Akt/NF?B pathway by DMA in response to radiation in tumor tissues. A single dose of DMA before TBI protect mice from GI and HP acute radiation syndrome (ARS) and offered radioprotection through oral, i.v., i.p., and s.c route of administration. The half life of DMA in plasma is 3.5 h at oral dose and 90% clearance was observed in 16 h. DMA accumulates in high concentration in intestine, liver, kidney and spleen tissues, justifying the observed radioprotection to normal tissue even at single dose.

Abstract: A recombinant microorganism is provided herein, in particular, a recombinant microorganism of the Azotobacteraceae family. The recombinant Azotobacter microorganism is capable of fixing atmospheric nitrogen continuously in the presence of oxygen and externally fixed nitrogen sources. The present invention further provides a process for production of the recombinant microorganism and a composition comprising the recombinant microorganism for use as biofertilizers and/or for use in the preparation of a fertilizer composition. The recombinant microorganism produced by this invention is an environmental friendly, highly beneficial microorganism.

Abstract: Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B. anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF of EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.

Abstract: The present invention relates to a method for identification and/or diagnosis of REM sleep loss. More particularly, the present invention relates to a method for identification and/or diagnosis of REM sleep loss from blood samples.